Oxlumo (lumasiran)
OrphanPRIME
- Region
- 🇪🇺 EU
- Active substance
- lumasiran
- Company
- Alnylam Netherlands B.V.
- Status
- Authorised
- Therapeutic area
- Hyperoxaluria, Primary
- CHMP opinion
- Thu 15 Oct 2020
- EU approval
- Thu 19 Nov 2020
- Designations
- Orphan, PRIME
- Application
- EMEA/H/C/005040
- ATC
- A16AX18
- Official record
- www.ema.europa.eu
Indication
Treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
Regulatory milestones
No milestones recorded in the last year.
Follow Oxlumo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.